Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children

PHASE2CompletedINTERVENTIONAL
Enrollment

367

Participants

Timeline

Start Date

October 28, 2021

Primary Completion Date

May 15, 2024

Study Completion Date

May 15, 2024

Conditions
Bordetella Pertussis, Whooping Cough
Interventions
BIOLOGICAL

BPZE1 pertussis vaccine and placebo

Live attenuated pertussis vaccine and placebo

BIOLOGICAL

BPZE1 pertussis vaccine and Boostrix

Live attenuated pertussis vaccine and tetanus, diphtheria, and aP vaccine

BIOLOGICAL

Placebo and Boostrix

Tetanus, diphtheria, and aP vaccine and placebo

Trial Locations (16)

Unknown

Sydney Children's Hospital, Randwick

Sydney Children's Hospital, Westmead

Women's and Children's Hospital, North Adelaide

University of Melbourne, Melbourne

Telethon Kids Institute, Nedlands

CSA Clinica San Augustin, San José

IICIMED Instituto de Investigacion en Ciencias Medicas, San José

MRI, Metropolitan Research Institute, San José

Birmingham Children's Hospital NHS Foundation Trust, Birmingham

Bradford Royal Infirmary, Bradford

Bristol Royal Hospital For Children, Bristol

Addenbrooke's Hospital, Cambridge

Leicester Children's Hospital, Ward 14, Level 4,, Leicester

St George's Healthcare NHS Trust, London

Oxford Vaccine Group, Oxford

University Hospital Southampton NHS Foundation Trust, Southampton

Sponsors
All Listed Sponsors
lead

ILiAD Biotechnologies

INDUSTRY